Drug Trial Radar · NCT04198558
A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Oct 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Nov 29, 2019
Primary completion
Feb 23, 2022
Study completion Feb 23, 2022
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomised, placebo-controlled study of the safety and tolerability of single doses of MEDI0618 in healthy volunteer subjects.
Conditions
- Chronic Pain
Interventions
MEDI0618Drug
MEDI0618 A novel human immunoglobulin antibody
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Up to 85 days
- Incidence of Treatment-Emergent Serious Adverse EventsTime frame: Up to 85 days
- Vital SignsTime frame: Up to 85 days
- Vital SignsTime frame: Up to 85 days
- Body WeightTime frame: Up to 85 days
- HeightTime frame: Up to 85 days
- Clinical ChemistryTime frame: Up to 85 days
- HaematologyTime frame: Up to 85 days
- Thyroid FunctionTime frame: Up to 85 days
- Renal FunctionTime frame: Up to 85 days
- UrinalysisTime frame: Up to 85 days
- 12-Lead ElectrocardiogramTime frame: Up to 85 days
- Physical ExaminationTime frame: Up to 85 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Berlin, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.